HC Wainwright & Co. Reiterates Buy on Evommune, Maintains $50 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.1%

Neg 0% Neu 91.1% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Buy and maintains $50 price target.